DNDi and Novartis initiated a collaboration and licence agreement in early 2020 to jointly develop LXE408 – a first-in-class compound, discovered at Novartis with financial support from Wellcome – as a potential new oral treatment for visceral leishmaniasis.

Project updates


A Phase I multiple ascending dose study of LXE408 began in 2020 but faced delays due to the COVID-19 pandemic. Results are expected in mid-2021. Planning is underway for a Phase II study to commence in India in 2022.